The pandemic coronavirus disease 2019 (COVID-19) has spread vastly on a global scale. There is no definitive treatment of the disease till now. However, prevention and symptomatic management is the prime choice. COVID-19 patients suffer from various secondary infections such as pneumonia, severe respiratory disease, and heart complication but super-infections and co-infections in COVID-19 pneumonia are still under exploration. Secondary infections are more common in severely ill COVID-19 patients, fungal infections being 10 times more common. Severe complication of coronavirus disease with secondary infection with fungus is very dangerous and life threatening to patients. This is the black fungus disease that is known as mucormycosis. Steroids and other immunosuppressive drugs are being used in the treatment of COVID-19 which is resulting into further complications. The side effects include increased secondary infections, immune modulation, manifestation of latent diabetes mellitus (DM), dizziness, weight gain, mood changes, insomnia, and muscle weakness . The incidence rate of mucormycosis globally is 0.005–1.7 per million. In Indian population, its prevalence is 0.14 per 1000, which is about 80% higher than other developed countries. The fatality rate of mucormycosis is 46% worldwide. Mucormycosis is also known as Zygomycosis and now it’s called black fungus disease. It’s a serious fungal infection disease which is a secondary complication of coronavirus disease. It mostly infects sinuses, brain causing headache, epistaxis, fever, etc.. Patient who is already suffering from diabetes, blood disorders, AIDS, or has history long-term use of steroids are prone to be affected with secondary infection of mucormycosis .
